Patents by Inventor Damian Medici

Damian Medici has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for using synthetic triterpenoids in the treatment of bone or cartilage diseases or conditions
    Patent number: 8921340
    Abstract: The present invention features the use of a synthetic triterpenoid to induce gene expression and differentiation of stem or progenitor cells in the treatment of bone/cartilage diseases or conditions.
    Type: Grant
    Filed: May 8, 2012
    Date of Patent: December 30, 2014
    Assignees: Trustees of Dartmouth College, Rutgers, The State University of New Jersey, The United States of America, as represented by the Secretary Department of Health and Human Services
    Inventors: Michael B. Sporn, Karen T. Liby, Gordon W. Gribble, Nanjoo Suh, Damian Medici, Pamela Gehron Robey
  • METHODS FOR USING SYNTHETIC TRITERPENOIDS IN THE TREATMENT OF BONE OR CARTILAGE DISEASES OR CONDITIONS
    Publication number: 20140377235
    Abstract: The present invention features the use of a synthetic triterpenoid to induce gene expression and differentiation of stem or progenitor cells in the treatment of bone/cartilage diseases or conditions.
    Type: Application
    Filed: September 10, 2014
    Publication date: December 25, 2014
    Inventors: Michael B. Sporn, Karen T. Liby, Gordon W. Gribble, Nanjoo Suh, Damian Medici, Pamela Gehron Robey
  • METHODS OF INDUCING CHONDROGENESIS IN MESENCHYMAL STEM CELLS USING SYNTHETIC TRITERPENOIDS
    Publication number: 20140328809
    Abstract: The present invention relates to methods for enhancing differentiation of mesenchymal stem cells into chondrocytes and/or inducing chondrogenesis. The invention also relates to applications in the treatment of diseases which can affect cartilage (chondrodystrophies). The present invention also relates to methods of treatment comprising establishing a population of chondrocytes from a population of mesenchymal stem cells, which have been induced to differentiate with a synthetic triterpenoid, and administering the population of cells to a patient.
    Type: Application
    Filed: November 14, 2012
    Publication date: November 6, 2014
    Inventors: Gordon W. Gribble, Damian Medici, Pamela Gehron Robey, Karen T. Liby, Michael B. Sporn, Nanjoo Suh
  • CONVERSION OF VASCULAR ENDOTHELIAL CELLS INTO MULTIPOTENT STEM-LIKE CELLS
    Publication number: 20130078718
    Abstract: Disclosed herein is a method of producing multipotent cells, comprising, activating ALK2 of isolated endothelial cells in a serum starved environment, to thereby produce isolated multipotent cells. Activation can be following a threshold period of serum starvation. Activating ALK2 is by contacting the isolated endothelial cells with TGF?-2 and/or BMP4. The isolated endothelial cells may be human, such as primary vascular, primary microvascular endothelial cells, primary human umbilical vein endothelial cells (HUVEC) or primary human cutaneous microvascular endothelial cells (HCMEC). The activation of ALK2 significantly decreases expression of VE-cadherein of the cells and/or significantly increases expression of one or more of STRO-1, FSP-1, ?-SMA, N-cadherin, fibronectin (FN1), Snail (SNAI1), Slug (SNAI2), ZEB-1, SIP-1, LEF-1, Twist, CD10, CD13, CD44, CD73, CD90, CD120A, and CD124.
    Type: Application
    Filed: March 9, 2011
    Publication date: March 28, 2013
    Applicant: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Damian Medici, Bjorn Olsen